This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk04: Welcome to the CareCloud Inc. 3rd Quarter 2023 Results Conference Call. At this time, all participants will be in a listen-only mode. Later, we will conduct a question-answer session. I will now turn the call over to your host, Natalie Garcia, CareCloud's General Counsel. Ms. Garcia, you may begin.
spk02: Good morning, everyone. Welcome to the CareCloud 3rd Quarter 2023 Conference Call. On today's call are Mahmood Haque, our Founder and Executive Chairman, Hadi Chowdhury, our Chief Executive Officer, President, and the Director, and Larry Steenvorden, our Chief Financial Officer. Before we begin, I would like to remind you that certain statements made during this conference call are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934 as amended. All statements other than statements of historical fact made during this conference are forward-looking statements, including, without limitation, statements regarding our expectations and guidance for future financial and operational performance, expected growth, business outlook, and potential organic growth and acquisition. Forward-looking statements may sometimes be identified with words such as will, may, expect, plan, anticipate, upcoming, believe, estimate, or similar terminology and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control. which could cause actual results to differ materially from those contemplated in these forward-looking statements. These statements reflect our opinions only as to the date of this presentation, and we undertake no obligation to revise these forward-looking statements in light of new information or future events. Please refer to our press release and our reports filed with the Securities and Exchange Commission where you will find a more comprehensive discussion of our performance and factors that could cause actual results to differ materially from these forward-looking statements. For anyone who dialed into the call by telephone, you may want to download our third quarter 2023 earnings presentation. Please visit our investor relations site, ir.carecloud.com. Click on News and Events, then click IR Calendar, click on third quarter 2023 results conference call and download the earnings presentation. Finally, on today's call, we may refer to certain non-GAAP financial measures. Please refer to today's press release announcing our third quarter 2023 results for a reconciliation of these non-GAAP performance measures to our GAAP financial results. With that said, I'll now turn the call over to our CEO, Hadi Chowdhury. Hadi?
spk06: Thank you, Natalie, and thanks to all of you for joining our third quarter 2023 earnings call. I have several meaningful updates to provide from the quarter, but first, we will start with a quick review of the quarterly results. In the third quarter, revenue came in at $29.3 million and adjusted EBITDA came in at $3.2 million. Larry will dive deeper into these numbers later in the call. Overall, our recent progress on several fronts gives us confidence that the fundamentals of our business are intact and CareCloud remains on track to return to growth next year. As an example, we are pleased to report that after the close of the quarter, we signed a credentialing contract with an existing force customer that we believe has potential to be quite significant. Implementation of this is already underway, so we can expect to recognize a portion of that revenue before E&A. This quarter, we continue to make meaningful progress on several ongoing projects and goals, including the launch of our generative AI solution, the stabilization of MedSR, our project-based professional service businesses, and the decisive action we took to align our cost infrastructure to our highest value business opportunities. Digging deeper into our progress in the third quarter, I will start with an update on generative AI. We recently launched our Cirrus AI solution, which incorporates generative AI technology. Just two weeks ago, we had the opportunity to demonstrate this solution at a Google-sponsored conference that brings together thought leaders across the healthcare industry. To kick off our go-to-market strategy for this solution, Through the end of the year, we will be offering it to our client base free of charge. This trial period will allow them time to better understand the benefits and how they can leverage them in their specific practice. They will then have the opportunity to purchase the competitively priced solution starting in 2024. In total, we have launched three AI solutions, two for EHR and one for RCM, and that is just the tip of the iceberg for us. We believe that our ability to stay ahead of the curve on the latest technology will give us a competitive edge in the market by improving the commercialization of our solution and are actively working on additional features. Over the past few months, we have taken effective steps towards stabilizing our Medisat professional services business. We have continued to strengthen our relationship with Meditech one of the dominant EHR provider, and over the past two years, Medisar has evolved from a consultancy firm that mainly relied on short-term staffing projects for a single vendor to a more diversified and sustainable revenue model. Our RCM practice has grown by almost 300% since 2021, and we also see a strength with our technology transformation practice. We are optimistic for 2024 as we see a significant shift in our professional services MED-SR pipeline mix towards RCM and tech transformation and a strong demand for these solutions. In addition, today we have $30 million in active pipeline opportunities versus $12 million entering 2023. We are confident because of the pipeline size and mix that we can leverage our expertise and reputation to capture opportunities and deliver value to our clients and shareholders. Lastly, as we announced in an 8K in early October, we are actively working on improving profitability and positive free cash flow by aligning costs with highest return opportunities. We expect most of the positive impact will be realized in 2024. Larry will discuss this in more detail in a few minutes. All of these factors, just discussed, give us increased confidence that we can return to profitable growth next year. Turning to an update on our business opportunities. As discussed earlier this year, we revamped our website to enhance the user experience and highlight all of our solutions. Our next generation end-to-end therapy solution is live on our upgraded website, and we recently launched a marketing campaign to highlight this offering. We are confident that this campaign, along with the new website, will go a long way in raising awareness of this solution in the physical therapy market. Next, I will provide an update on our opportunity in the Middle East. We are pleased to announce that we are making meaningful progress on our global expansion efforts in that region. We have been strengthening our business development and establishing a permanent presence in Dubai UAE near the innovation and technology hub of Dubai Internet City. Our product teams have been ensuring that our system adhere to the UAE health data law, which requires that health data is stored within the country And at the same time, we are working diligently to integrate our system with the national database, which operates similarly to a health information exchange. We are also excited to present our solutions and services at Arab Health Conference in Dubai in Q1 of 2024. Arab Health is one of the largest healthcare conferences with over 100,000 expected attendees from 180 countries. We look forward to providing you an update on our earnings call next year. In terms of upcoming milestones, CareCloud is preparing to launch CareCloud Prime, a state-of-the-art cloud-based electronic health record platform designed to meet modern physicians' demands. Formerly known as CareCloud Go, this project was a significant goal following CareCloud's acquisition a few years ago. A Cloud Prime offers advanced features such as cloud-based accessibility, seamless interoperability, user-friendly design, improved patient engagement, and AI-powered clinical decision support. It includes tools like CirrusChat for staff interactions, global search for navigation, and unified patient records for efficient data exchange emphasizing efficiency. It also provides health providers with customizable templates, as well as provides support for value-based care model tools, such as proactive care management, remote patient monitoring, and seamless telehealth integration. K-Cloud Prime is more than just another product in our portfolio. It represents our commitment to continually improve and innovate to better serve our clients' evolving needs. In summary, Although we faced some headwinds this year, we entered the fourth quarter feeling confident after the steps we took to stabilize the business and reprioritize cost structure. Because of these strategic actions, we believe we have made it past our low point and are on upswing. The steps we have taken and the progress made this quarter give me confidence in reiterating our full year guidance and our ability to return to growth in 2024. Now I will turn the call over to Larry to give you a closer look at the numbers. Larry?
spk12: Thank you, Hadi, and good morning, everyone. Before I review the third quarter results, I want to share a little more detail on our recent cost realignment initiative. The third quarter is my first full quarter as Cara Cloud's CFO. I took a fresh look at our cost infrastructure and, along with Hadi and the board, we made some tough but necessary decisions to pare back in certain areas of the business. As you know, transformation decisions are difficult, but the goal was to ensure the company continued investing in growth while also establishing a sustainable foundation for improvements in positive free cash flow and profitability. Most of the actions are scheduled to take place in the fourth quarter, but I anticipate some will carry over into 2024. We expect these changes in our expense profile to result in approximately $10 million of annualized free cash flow improvement. Approximately $5 million is related to operational expense savings, and the other half includes the completion of R&D investments, specifically our next-generation CareCloud Prime platform that Hadi just discussed. This has a two-fold benefit for us. First, we will see a notable reduction in our capitalized software going forward. And second, we now anticipate realizing the ROI for these investments. Now turning to the third quarter results. Revenue of $29.3 million was leveled sequentially and compared to $33.7 million year over year. The primary reason for the year over year decline was a loss of the two customers due to health systems mergers. Our wellness offering continues to gain traction, showing growth in the monthly sequential number of patients. Adjusted EBITDA for the quarter of $3.2 million reflects a margin of 11%. This compared to an adjusted EBITDA of $4.8 million a year ago. The decline in quarterly EBITDA was a combination of lower revenue and related margins partially offset by lower selling, marketing, general, and administrative costs in the current period. Turning to the balance sheet and cash flow, at the end of the third quarter, we had a $6.4 million in cash and net working capital of $5.5 million. Cash provided by operations was $4.3 million, and there was $3.2 million in net cash used in investing activities. Finally, we are reiterating our 2023 guidance for revenue between $120 and $122 million and adjusted EBITDA between $15 and $17 million. A combination of factors, including the credentialing contract, Medisor's meaningful contract ramping, and continued solid execution in our core revenue cycle business provides the pathway to achieving our full year expectations. In conclusion, we have taken tough but necessary actions to realign for growth and steady improvement in our financial performance. I believe we'll not only end the year from a position of strength, but be better positioned going into 2024. With that, I'll now turn the call over to Mahmoud for his closing remarks. Mahmoud.
spk05: Thank you, Larry. As expressed earlier, we feel that our solutions are very well positioned in the marketplace. The team is ready and fully engaged to drive future success and shareholder value. I would like to thank our employees, customers, and shareholders for all they do to support CareCloud's mission. Let's open the call to questions. Operator?
spk04: Thank you. We will now begin the question answer session. To join the question queue, you may press star then one on your telephone keypad. You will hear a tone acknowledging your request. If you are using a speakerphone, please pick up your handset before pressing any keys. To withdraw your question, please press star then two. We will pause for a moment as callers join the queue. The first question comes from Jeffrey Cohen with Latimer Gallman. Steve, go ahead.
spk11: Good morning and thank you very much for taking the questions. Just a couple from our end. I guess firstly, for Larry, could you maybe equate the guidance and the adjusted EBITDA to free cash flow or cash production or net income?
spk10: We would have to put that out separately, Jeffrey. I absolutely can do that as a follow-up.
spk11: Okay, perfect. And then could you talk a little bit about the Cirrus AI arrangement with Google and which offering specifically that's going to pertain to and if that also ties over to the Prime platform that you plan to introduce?
spk06: Good morning, Jeff. Thank you. Thank you for the question. And generative AI, I think the most one of the biggest, the highest discussed topic nowadays in any industry. So for us too, as we mentioned earlier in the year, we started focusing towards how we can leverage this generative AI technology into our platform to help the healthcare market segment, the healthcare industry. So we are working on a number of other various different features to be incorporated, and we will keep on announcing as those features will be incorporated. But we started with, for now, we looked at on the both fronts, the back end improvement, how we can leverage the generative AI from where we can improve the revenue cycle management work by our employees, which later on will also be available in the SAS model. As you know, one of the complex procedures is the appeals process, where you need to appeal certain decisions of the insurance companies, especially into the out-of-network space or the worker comm space. So with the help of the generative AI, our system can systematically generate appeals And based on the internal testing, the result seems to be very promising, and we believe over the payment processing cycle as well as the collection through those appeals should improve with the help of that. On the front end, which is more important, we focused on, we thought the most important thing for any physician is the clinical decision. So when the patient walks in, in order to record the complete session where the doctor has to look at, for example, their medication, their lab history, their diagnosis, so many different pieces of information the provider has to look at and then come up with the next diagnosis and the test and the like. So think about this as either it's a second opinion or the system will suggest to the provider, these could be the potential diagnosis, procedures, these probably could be the suggestive orders, the lab test that the provider should order, and based on all that, gives them a recommendation. Now it's up to the provider to accept it as is or just look at it if there is certain aspects that needs to be changed, removed, and added, and can complete that. And it also even suggests the medicine, the medications. So I think the thing is this is In many cases, think about the rare diseases. It could be some instances where the provider may not be able to quickly diagnose and may have been able to diagnose after multiple visits. Now, with this help and this generative AI, as the model will keep learning more and more, the results will keep on improving. So we should be able to diagnose or treat those diseases much earlier than they would have. So from the business standpoint, so one is the adaptability. We need to make sure that the doctors and the users understand and realize the importance of such features. So we are turning it on at least for now until the end of the year, free of cost. There won't be any charge. It will be a risk-free trial. The clients can start using it, get accustomed to it. And then entering into the next year, we have a plan to start pricing it out on the license basis. We will announce the price once that gets finalized. And of course, the second thing is the market positioning, the marketability of our product. If you look at our competitor, I think all the competitors, everyone is trying to come up with some solution. So this is at the high level, and any further questions, I'll be happy to even connect with you offline to explain further.
spk11: Thank you, Hadi. That's helpful. And then lastly for us, could you give us a sense of your OUS business now and give us a sense of what you may anticipate going forward on growth or aggregate revenue for OUS?
spk06: Okay, so you probably are referring to our Middle East, the Middle East opportunity that we are focusing on. So we are making continuous progress, and for this year, as even on the last call I mentioned, our goal is to at least be able to sign at least a contract or a few contracts. and recognize some revenue into the next year. We will incorporate that, include that when we issue the guidance for the next year on the next earnings call. But in terms of our progress, if you think about it on the UAE side, there are a number of steps. One is incorporating the entity. We have completed that. Second thing is getting the license to conduct the business in different categories. So we have completed that. Third step is onboarding at least the management employees and certifying them so they should be able to transact the business in the UAE. So we are in this third process. On the other side, two other fronts. One, we are actively working on at least three, one large and two smaller opportunities there. And on our technical side, the IT side, they have to make sure that our products certify to the local requirements, such as making sure the data stays within the UAE. And secondly, once we have a client, we have to start working with authorities to get the EHR and the different other items off the platform certified. I hope that answers the question.
spk11: Yes, perfect. Thanks for taking our questions.
spk09: Thank you.
spk04: The next question comes from Neil Chatterjee would be Riley. You go ahead.
spk08: Good morning and thanks for taking our questions. Just maybe just on the quarters. Maybe just wanted to just see if you talk more about any any seasonality you might have seen, you know, in 3Q and what kind of gives you the confidence and and I guess that kind of the sequential ramp or strength at the fourth quarter. uh with reaffirming the full year guidance uh you know was there any you know med sr projects impact that that might have shifted from 3q to 4q
spk10: Yeah. Hi, Neil. It's Larry. So thanks for the question.
spk12: As we look at Q3 to Q4, you know, the Q3 season now really similar to Q3 of last year. Again, the big impact just year-over-year comparison was the two large health system mergers. Now, as we look at Q4, a couple key factors, you know, one certainly is the professional services, MedSAR, you know, really great developments there on some of the contract wins.
spk10: Also, we put out the press release about the credentialing and the revenue that we're going to start to recognize a portion of that Q4. So we reiterated our full year guidance. Can you hear us?
spk08: Yeah, sorry, I wasn't sure if you were done.
spk06: Oh, okay. Yeah. Okay, no, sorry. It looks like the phone went off. Yeah, no, we were off.
spk12: So just complete that. So, yeah, the MetaSAR is really the key driver in Q4. And then also just our core RCM. Business will, with the solid execution, will also support the confirmation for the full year guidance. So all that has really come together and it just gives us confidence also going into 2024 with our backlog. We commented on where we are. Also with the professional services going into the next year. So really come together. And, you know, as we looked at 2023, it's a transformation year from the health system mergers and just setting us up for growth into 2024. But, you know, we want to get there for the finish strong and then go into the next year from that same position of strength.
spk08: Great. And just maybe just one follow up on that, just in terms of, you know, kind of on that MetaSR business. I mean, just looking at the chart with kind of the mix, you know, look like, you know, Meditech and RCM had kind of grown in the mix. What's driving some of that traction you're getting on that side?
spk06: I think, and we have, just to clarify, we have Dwight Garvin, who is heading the Medisar business, so that I can start and then he can finish the question. If you think about it, the overall industry, the largest players in the health system space is, let's say, somewhere between 40% to 50% market share. So that's the relation we lost. So until we acquired Medisar, the primary focus of the organization was in terms of bringing the business in, was that one the topmost player in the market. Once we lost that opportunity, so we started working towards the next in the line, and Meditech is among the top three, I would say, in that space. So over the time, over the last one year, we have been able to reestablish not only our relationship with Meditech, but in addition to that, our marketing strategy was more oriented towards finding the opportunities for Meditech. So that's one. The second one is the RCM. When we acquired Amerisar, their RCM-related revenue was hardly $1 million out of $30 million roughly that they were doing. That has improved by multiple fold now because that was also, if you remember, one of our narrative or one of our reason for the acquisition that these health system relationships, we should be able to leverage those Because those relationships, we can now talk to the CEO, the CFO there, and should be able to cross-sell and up-sellable RCM services. So those two are seems to be becoming the primary drivers of our Medisar or updated Medisar, the business. Those are the two major contributors. But Dwight, if you would like to add anything, please go ahead.
spk00: Sure. Thank you, Heidi. And just to kind of expound upon what Heidi said, what we're seeing in our RCM space is really moving from that advisory model where you have short-term engagements and moving those advisories into more of a managed services. So now we can take our relationships established throughout all the other practices, sell them to RCM advisory services, then turn those into long-term recurring revenue managed services models. And that's really what we're kind of targeting. And at the same time, expanding on our Meditech business, really making some very key hires in the business development side this year, and those have allowed us to really strengthen that partnership within Meditech.
spk09: I hope that answers your question. Yeah, great. Thanks for that, and I'll hop back in the queue. Thanks, Ian.
spk04: Once again, if you have a question, please press star, then one. The next question comes from Alan Cleave with Maxim Group. Please go ahead.
spk07: Yes. Good morning. For the CareCloud Prime offering that's coming, talk about how that compares to what you have today and how you think about Would this be an upsell to existing clientele or new customers, and would there be a price differential? Just help us understand a little more about that. Thank you.
spk06: Thanks, Alan. Good morning. Thanks for the question. So there are a couple of aspects, a couple of ways here we need to look at. One is every time, and if you go back, our first system was in 2004, 2005, our first generation of the entire solution. And then we kept bringing the new next generation solutions after every couple of years. And the reason that triggers is one is the compliance requirement or the regulatory requirements or the market expectation, what are the new features that's needed. And the other side is the technology platforms. This is a very rapidly changing the world. Every after five, six years, the technology becomes almost obsolete. And in order to have a more viable, reliable, and effective product, you need to bring the products to the next technology platform. So this one on the technological perspective, this will be on the new backend technology. The second thing is it will have more features. We are focusing to have it more features towards value-based care models, preventive medications, the preventive health care and the like, and a number of other things, more effective, better chart-sharing model versus the previous model. So I think all of those things together. And another key aspect is When we acquired CareCloud Help, they were working on this platform for the last number of years. And for us, we had another platform, which we call TalkEHR. So both of those platforms are in today's world are active. We can We can sign up the client, they can service the client, both the platform are the certified platform. So this is going to be our next generation with ultimately over the next number of years, both of those two sets of client we expect, we foresee would be transitioned into this futuristic platform. We're not planning on doing it starting next month. Whoever would like to transition at their own, we would love to bring them onto this new platform as a seamless transition, no additional and extra cost for them. So this will become our flagship platform going forward with the next generation of healthcare features and capabilities and the technology platform.
spk07: Thank you. My other question is, if you could just talk a little bit about the credentialing contract and what you're doing and how you think about the opportunity there.
spk06: Great question, Neil. And credentialing, and we have Carl with us too, and he's the one who was working on this relationship. I can get started and then we'll hand it over to Carl. So from the service or the product, when we talk about our end-to-end revenue, tech-enabled revenue cycle management services, The first piece into the revenue cycle, we believe, is start or begin with the credentialing. So if you do not credential a client effectively, we won't be able to generate the revenue. Even if the provider sees the patient, the reimbursement either will not happen or will not come at the optimal level it should come. We have been working on our side internally on building up a platform which can help us at the backend help us track systematically more effectively the applications that we have filed wherever the electronic application submission is possible. System has the capability to do that. Now it flags the application that needs the follow-up. And now also with the help of the different AI, many of the applications can be completed systematically without any human intervention, which improves the accuracy level and also the staff time. That's one. We also have been, and we mentioned in one of the last, when we announced this as part of that release, we are working on delegated credentialing certification, like establishing a CBO. Think about that CBO as, The insurance company has delegated their credentialing role to the company. So hypothetically talking, if a commercial insurance take at an average 20 days to credential a provider, we believe internally we should be able to credential the same provider at, let's say, five days instead of the 20 days. So this is our overall credentialing capability has become very much strengthened, and we think that we can go out and start marketing the credentialing more effectively. So with that, this is our first large contract we have been able to sign in Vaynerchuk. Just share some details, please.
spk01: Yes. So the relationship met a need of the customer. to make sure that their clients were credentialed so that when they were doing revenue cycle work, they were getting paid for those services. We were able to come in at a price point and a cost structure that was incredibly attractive to them, along with our existing resources that are trained and up to speed. And as Hadi mentioned, the delegated credentialing piece is huge and takes a long time to take care. We've really leveraged our offshore resources. So we've been doing credentialing for our own clients for many, many years. And this happened to really fit a need and have gone further. And that's actually opened up some doors for some additional discussions with some other large companies that need this on a back end. So we really think that there's an untapped market for this to come at it in a way that is much more cost effective than those companies that are dedicated credentialing companies. It also has the distinct advantage of You know, having one-stop shopping, so if we're helping with RCM services or software services, credentialing is a very natural add-on functionality.
spk06: And Aaron, just to give you some idea in terms of the revenue from this opportunity, as we mentioned that it's the tens and thousands of providers that we will be positioning or presenting this solution to with their help. And only at 5% penetration into that client base, we are expecting, I would say, something over a million dollars in annualized revenue. So that's a 5% penetration. So there's a big opportunity there. And as Carl mentioned, this will become a good first case study or a model for us to go and sell the similar with other larger opportunities.
spk04: Thank you very much. This concludes the question and answer session. I would like to turn the conference back over to Natalie Garcia for any closing remarks.
spk03: On behalf of the company, I'd like to thank everyone who has joined us on today's call. We appreciate your participation and your interest in us as a company and we look forward to speaking with you again. Thank you everyone and have a great day.
spk04: This concludes today's conference call. You may disconnect your lines. Thank you for participating and have a pleasant day.
Disclaimer